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independently associated with OA severity (KL score), WOMAC pain and
elevations of biomarkers – PGE2 and COMP fragments. Our data suggest
that increased iron (ferritin levels) may promote cartilage damage in
patients with knee OA and merits further investigation as a biomarker
of disease severity and progression.
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SAFETY AND EFFICACY OF NSAIDs IN ELDERLY ARTHRITIS PATIENTS:
A SUBGROUP ANALYSIS
H. Kellner1, M. Essex2, C. Li3. 1Div. of Rheumatology, Ctr. for Inﬂammatory
Joint Diseases, Munich, Germany; 2Pﬁzer Inc, New York, NY, USA; 3Pﬁzer
Inc., New York, NY, USA
Purpose: As increasing age is a well-known risk factor for gastrointestinal
(GI) adverse events and may contribute to reduced compliance and
discontinuation of therapy, we set out to compare the safety and efﬁcacy
of celecoxib vs diclofenac slow release (SR) plus omeprazole in elderly
patients with arthritis.
Methods: Patients aged ≥65 years, with osteoarthritis and/or rheumatoid
arthritis at increased GI risk who participated in the CONDOR trial
(Celecoxib vs Omeprazole and Diclofenac in Patients With Osteoarthritis
and Rheumatoid Arthritis) were included in this subgroup analysis. The
CONDOR trial was a 6-month, prospective, double-blind, randomized
clinical trial of celecoxib vs omeprazole and diclofenac SR. Eligible
patients were expected to need nonsteroidal anti-inﬂammatory drugs
(NSAID) therapy for at least 6 months; aspirin or antiplatelet users
were excluded. Patients were Helicobacter pylori negative. The primary
end point was a composite of clinically signiﬁcant upper and lower GI
events adjudicated by an independent blinded expert committee and
analyzed using a life-table method. Patients were randomized to either
celecoxib 200mg bid or diclofenac SR 75mg bid plus omeprazole 20mg
qd. Follow up visits were at 1, 2, 4, and 6 months from baseline. Efﬁcacy
was determined by Patients’ Global Assessment of Arthritis at each visit.
Results: 2446 patients aged ≥65 years comprised the intent-to-treat
population (n =1219 celecoxib; n = 1227 diclofenac SR). Mean (SD) age
was 70.4 (4.5) years for both arms; 83.0% of celecoxib and 80.8% of
diclofenac SR patients were female. The majority of patients were
white (54.1% celecoxib; 52.2% diclofenac SR). The difference between
the 2 incidence proportions of adjudicated primary GI end points in
patients aged ≥65 years, controlling for region, history of gastroduodenal
ulceration, and time-block was statistically signiﬁcant (odds ratio, 6.27;
P < 0.0001 favoring celecoxib). 76.9% of celecoxib and 72.0% of diclofenac
SR patients completed the study. Among those treated, 9.5% and 14.3%
of patients, respectively, discontinued treatment for reasons related to
study drug, and there were 2 deaths in the celecoxib arm and 1 in the
diclofenac SR arm. Patients’ Global Assessment of Arthritis was 3.2±0.7
at baseline and 2.4±0.8 at Month 6 for both celecoxib and diclofenac SR,
respectively. Similar percentages of patients rated efﬁcacy at good/very
good at baseline and Month 6 for celecoxib (10.5%, 55.9%) and diclofenac
SR (10.6%, 56.4%). Least squares mean (SE) at Month 6 (last observation
carried forward) was 2.539 (0.034) and 2.521 (0.033) for celecoxib and
diclofenac SR (P=NS), respectively.
Conclusions: The results of the CONDOR trial, in which celecoxib was
superior to diclofenac SR plus omeprazole in reducing the risk of clinical
outcomes across the entire GI tract, were conﬁrmed in a subgroup
analysis of patients ≥65 years. The safety and efﬁcacy of both treatments
was comparable in this population. These data may help physicians make
more informed decisions in treating elderly patients with arthritis.
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Purpose: Intra-articular (IA) injection of hyaluronate (HA) has been
shown to be safe and effective for relieving pain in patients with
osteoarthritis (OA) of the knee and is recommended for patients who
cannot be effectively managed with non-pharmacologic interventions or
simple analgesics. Although many studies support the safety and efﬁcacy
of single course IA-HA injections, fewer trials have evaluated the risks and
beneﬁts of repeated series of injections. This 26 week Extension Study of
the FLEXX Trial was conducted to evaluate the safety of repeated intra-
articular (IA) injections of Euﬂexxa® (1% sodium hyaluronate; IA-BioHA)
for painful knee osteoarthritis (OA).
Methods: Participants who completed the randomized, double-blind,
26-week FLEXX Trial and who elected to participate in the Extension
Study received asecond series of3 weekly IA-BioHA injections and were
followed for an additional 26 weeks. Adverse events (AEs) were recorded
and the effect of treatment on knee pain was measured following a 50-
foot walk test using a 100mm visual analog scale (VAS). The 3 subscales
of WOMAC, OARSI responder rate, Patient Global Assessment, SF-36, and
intake of rescue medication was also evaluated.
Results: TheFLEXX Trial included 588 subjects with painful knee OA
who received 3 weekly IA injections of either BioHA or buffered saline
(IA-SA). Results from the FLEXX Trial showed that IA-BioHA decreased
mean pain 100mm visual analog scale (VAS) scores immediately after
a 50-foot walk test by −25.7mm versus −18.5mm for the IA-SA group.
Both treatments were well tolerated with about 1% of subjects in each
group reporting injection site reactions.
The Extension Study included 433 subjects, 219 who received IA-BioHA
and 214 who received IA-SA during the FLEXX Trial. Safety results from
the Extension Study indicate that 43.4% (188/433) of subjects had AEs,
of which 4.8% (21/433) were deemed treatment-related AEs. Two AEs
in the Extension study led to discontinuation, and no joint effusion was
reported. Patients who continued with IA-BioHA in the Extension Study
maintained their improvement from baseline, with an average further
reduction in pain VAS score of −3.5mm. Patients initially treated with
IA-SA in the FLEXX Trial also had a reduction in pain VAS score of
−9.0mm. The OMERACT-OARSI responder rate for all subjects was 75.3%
at the completion of the Extension Study. WOMAC Pain, Stiffness, and
Disability scores decreased by 47.2%, 42.5%, and 44.1%, respectively. The
Patient’s Global Assessment improved an additional −8.1mm and there
were 15.2% and 15.7% improvements for SF-36 physical functioning and
bodily pain scores, respectively, from the beginning of the FLEXX Trial to
the end of the Extension Study. Acetaminophen use was reduced from
14.6 to 9.5 tablets per week, representing an overall 34.9% reduction
from the beginning of the FLEXX Trial.
Conclusions: Repeated injections of IA-BioHA were effective, safe, and
well-tolerated, and were not associated with an increase in AEs such
as synovial effusions. Additional symptom improvements during the
Extension Study were noted for subjects who received either IA-BioHA
or IA-SA during the FLEXX Trial.
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Purpose: Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are a common
class of medication taken for acute arthritic pain. However, associated
adverse events (AE) have prompted the development of new
formulations that minimize AEs and maintain efﬁcacy. The purpose
of this clinical study was to evaluate the analgesic efﬁcacy and
safety of an investigational, proprietary, nano-formulated, oral diclofenac
(diclofenac-N) compared with placebo in subjects with acute dental
pain.
Methods: This was a phase-2, multisite, randomized, double-blind,
single-dose, parallel-group, active- and placebo-controlled study. In total,
200 subjects who were 18–50 years of age, had extraction of ≥2 third
molars (at least one of which had to be a fully or partially impacted
mandibular third molar), and experienced moderate to severe pain
intensity within 6 hours after surgery were enrolled. Subjects received
either diclofenac-N 35mg or 18mg, celecoxib 400mg, or placebo. The
primary efﬁcacy variable was the sum of total pain relief (TOTPAR) over
0–12 hours (TOTPAR-12) after Time 0. Higher scores indicated better
pain relief. TOTPAR-8 and TOTPAR-4 were also evaluated.
Results: Diclofenac-N was signiﬁcantly (p < 0.001) better than placebo
for TOTPAR-12. Mean±SD TOTPAR-12 values for diclofenac-N 35mg,
diclofenac-N 18mg, celecoxib 400mg, and placebo were 16.81±12.76,
17.76±13.76, 14.61±15.05, and 5.65±11.53, respectively. TOTPAR-4 and
TOTPAR-8 values for diclofenac-N 35mg and diclofenac-N 18mg
demonstrated comparable results when compared to placebo. The
difference in time-to-onset of analgesia between each treatment
